RxDoctor Payments DataLook up a doctor →

James Leavitt, MD

Gastroenterology · Miami, FLNPI 1598740557

Payments from drug & device makers

$605,668in general payments, 2019–2025

Across 356 payments — averaging $1701.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$575K
  • Teva Pharmaceuticals USA, Inc.$13K
  • Echosens North America, Inc.$4K
  • Pentax Of America, Inc.$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • plus $7K from 35 others

What the payments were for

  • Consulting fees$4,10123%
  • Speaking & faculty fees$6,10034%
  • Food & beverage$7,52642%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$605,668 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$192,869
Medicare patients
333
Services billed
5,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab25$680,850
RinvoqUpadacitinib17$184,217
Mesalamine54$25,025
LinzessLinaclotide20$19,139
SutabSod Sulf/Pot Chloride/Mag Sulf57$9,285
ClenpiqSod Picosulf/Mag Ox/Citric Ac38$6,490
Omeprazole282$5,271
Budesonide EcBudesonide18$3,830
Mercaptopurine14$2,226
Pantoprazole Sodium75$1,418
CholestyramineCholestyramine (With Sugar)12$1,392
Dicyclomine Hcl17$605
Esomeprazole Magnesium11$318
Famotidine21$274
Prednisone11$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,031$680,85025 claims
AbbVieRinvoq, Linzess$1,576$203,35737 claims
Braintree Laboratories, Inc.Sutab$13$9,28557 claims
Ferring Pharmaceuticals Inc.Clenpiq$17$6,49038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →